GALECTIN THERAPEUTICS INC
Clinical-stage biopharma developing therapies for fibrotic diseases, liver disease, & cancer.
GALT | US
Overview
Corporate Details
- ISIN(s):
- US3632252025
- LEI:
- Country:
- United States of America
- Address:
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, 30071 NORCROSS
- Sector:
- Manufacturing
Description
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GALECTIN THERAPEUTICS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GALECTIN THERAPEUTICS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GALECTIN THERAPEUTICS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
